FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)

View source ↗

Summary

The FDA approved a supplemental application for BALVERSA (erdafitinib) submitted by Janssen Products LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

SUPPL AP for BALVERSA (ERDAFITINIB)